eligibility_summary
Adults ≥18 with met/recurrent non‑sq EGFRm NSCLC. Part I: PD on ≥1 EGFR TKI. Part II: C1 PD on osimertinib/other TKIs, C2 1L osimertinib <12 wks with persistent EGFR ctDNA (wk 6–12). ECOG 0–2, measurable, biopsy tissue, brain mets allowed, washouts/AEs resolved. Exclude: ILD/pneumonitis, SCLC, carotuximab/CD105, surgery, uncontrolled HTN, bleeding risk/thrombolytics, antibody allergy, HHT, drainable effusions, LMD, CV event, pregnancy/breastfeeding.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
Interventions: Osimertinib (Tagrisso) — oral small‑molecule, third‑generation, irreversible EGFR tyrosine‑kinase inhibitor selective for activating EGFR mutations (incl. T790M), suppresses EGFR signaling and tumor cell proliferation, with CNS penetration. Carotuximab (TRC105/ENV105) — intravenous monoclonal antibody against endoglin (CD105) on proliferating endothelial cells, anti‑angiogenic via blockade of TGF‑β/BMP9/10–ALK1/endoglin signaling and potential ADCC. Targets: Tumor cells harboring EGFR mutations (EGFR→RAS/RAF/MEK/ERK and PI3K/AKT pathways) and tumor vasculature (CD105+ endothelial cells, ALK1/SMAD pro‑angiogenic pathway). Aim: dual blockade of oncogenic EGFR signaling and tumor angiogenesis in advanced EGFR‑mutated NSCLC.